Literature DB >> 20620132

Hepcidin and iron metabolism: from laboratory to clinical implications.

Massimo Franchini1, Martina Montagnana, Giuseppe Lippi.   

Abstract

Hepcidin is a liver-synthesized hormone that inhibits the cellular efflux of iron by binding to ferroportin and its subsequent degradation. The main role of hepcidin is regulation of ferroportin expression and cell membrane function. Recent studies implicate hepcidin in a variety of iron disorders in addition to its primary role in the regulation of systemic iron homeostasis. Hepcidin excess has a key pathologic role in anemia of inflammation, chronic kidney disease, and iron-refractory iron deficiency anemia, while hepcidin deficiency is responsible for most cases of familial hemochromatosis and iron-loading anemia. The most important advances on the role of hepcidin in normal and abnormal iron metabolism and the main clinical and diagnostic implications are summarized in this review. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620132     DOI: 10.1016/j.cca.2010.07.003

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

1.  Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer.

Authors:  Reishi Toshiyama; Masamitsu Konno; Hidetoshi Eguchi; Ayumu Asai; Takehiro Noda; Jun Koseki; Kei Asukai; Tomofumi Ohashi; Katsunori Matsushita; Yoshifumi Iwagami; Daisaku Yamada; Tadafumi Asaoka; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Toshihiro Kudo; Taroh Satoh; Yuichiro Doki; Masaki Mori; Hideshi Ishii
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

2.  Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method.

Authors:  Sun-Il Hwang; Yong-Yook Lee; Jung-Ok Park; H James Norton; Elene Clemens; Laura W Schrum; Herbert L Bonkovsky
Journal:  Clin Chim Acta       Date:  2011-08-16       Impact factor: 3.786

Review 3.  Serum hepcidin concentrations and type 2 diabetes.

Authors:  Alex Aregbesola; Sari Voutilainen; Jyrki K Virtanen; Adeola Aregbesola; Tomi-Pekka Tuomainen
Journal:  World J Diabetes       Date:  2015-07-10

Review 4.  Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.

Authors:  Meredith A Atkinson; Colin T White
Journal:  Pediatr Nephrol       Date:  2011-03-13       Impact factor: 3.714

5.  Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer.

Authors:  Igor P Pogribny
Journal:  Breast Cancer Res       Date:  2010-10-06       Impact factor: 6.466

Review 6.  Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia.

Authors:  Faisal Nuhu; Sunil Bhandari
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-11

Review 7.  Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives.

Authors:  Ewa A Jankowska; Stephan von Haehling; Stefan D Anker; Iain C Macdougall; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2012-10-25       Impact factor: 29.983

Review 8.  Hepcidin and the iron enigma in HCV infection.

Authors:  Urania Georgopoulou; Alexios Dimitriadis; Pelagia Foka; Eirini Karamichali; Avgi Mamalaki
Journal:  Virulence       Date:  2014-03-13       Impact factor: 5.882

9.  Hepcidin Plays a Key Role in 6-OHDA Induced Iron Overload and Apoptotic Cell Death in a Cell Culture Model of Parkinson's Disease.

Authors:  Qi Xu; Anumantha G Kanthasamy; Huajun Jin; Manju B Reddy
Journal:  Parkinsons Dis       Date:  2016-05-19

10.  Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.

Authors:  Gregory D Lewis; Rajeev Malhotra; Adrian F Hernandez; Steven E McNulty; Andrew Smith; G Michael Felker; W H Wilson Tang; Shane J LaRue; Margaret M Redfield; Marc J Semigran; Michael M Givertz; Peter Van Buren; David Whellan; Kevin J Anstrom; Monica R Shah; Patrice Desvigne-Nickens; Javed Butler; Eugene Braunwald
Journal:  JAMA       Date:  2017-05-16       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.